New vaccine R&D platform by PerkinElmer makes Asia debut at CIIE

An innovative one-stop platform for the vaccine research and development by United States high-tech company PerkinElmer has made its Asia debut at the ongoing fourth China International Import Expo.

According to Zhu Bing, vice president of PerkinElmer, the new platform, which integrates robust testing and high-content screening technology, is one of 30 high-tech products the company is presenting at the expo. The company's innovations cover a wide range of health solutions from the R&D of new medication to quality control in pharmaceutical manufacturing to diagnosis and treatment of diseases.

The new technology, Zhu added, will significantly accelerate the development and clinical testing of both novel and traditional vaccines.

PerkinElmer had on Nov 6 also inked strategic partnerships with four Chinese companies during the CIIE. The companies are Biomarker Technologies Co. Ltd in Qingdao of Shandong province, Titan Scientific Co. Ltd in Shanghai, as well as Sinopharm Shanghai Medical Apparatus and Instruments Co. Ltd and Ruipu Pharma Co. Ltd in Hefei of Anhui province. The five parties have pledged to work together to advance the development of the bioscience and public health industries, especially in the area of testing and analytical technologies.

"I believe our collaboration will help introduce new products and services in the fields of bio-pharmacy, accurate diagnosis and treatment, and scientific research that are tailor-made for the Chinese market. Together, we will play a strong role in the development of China's health industry," said Zhu.